Drug EfficacyFDA approved GLP-1 agonists are correlated with a high levels adverse events, can have varying degrees of efficacy, and can fail to provide meaningful clinical benefit in a significant portion of the target patient population.
EarningsPalatin posted F3Q’24 earnings including EPS of -$0.53 vs. consensus of -$0.45, indicating lower than expected earnings.
Financial HealthWith less than six months' cash while starting multiple clinical trials, the price target for Palatin has been reduced from $5 to $3.